Tag: Incorporated

New York, June 25, 2025 (GLOBE NEWSWIRE) -- Eureka Acquisition Corp (the “Company”) (Nasdaq: EURK), a blank check company, today announced that in connection with its previously announced extraordinary general meeting in lieu of an annual general meeting of shareholders to be held on June 30, 2025, at 9:00 a.m., Eastern Time (the “Extraordinary General Meeting”), the Company has revised the contribution to its trust account and the terms and conditions in connection with the proposal to amend the Company’s current Charter (the “Charter Amendment Proposal”).

CUPERTINO, Calif., June 25, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that it intends to offer shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase shares of common stock in a public offering. All of the securities to be sold in the offering are to be offered by Reviva. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Mega Frenzy has launched a Real Money Social Casino to blend social play with the excitement of winning real money rewards through a digital one-stop solution.

LEHI, Utah, June 25, 2025 (GLOBE NEWSWIRE) -- Nature’s Sunshine Products, Inc. (NASDAQ: NATR) (“Nature’s Sunshine” or the “Company”), a leading manufacturer of high-quality herbal and nutritional supplements, today announced the launch of an underwritten secondary public offering of up to 2,854,607 shares of its common stock to be sold by Fosun Pharma USA, Inc (the “Selling Stockholder”).

DELTA, British Columbia, June 25, 2025 (GLOBE NEWSWIRE) -- WestBond Enterprises Corporation (TSX-V: WBE) has posted a loss of $52,380 for the year ended March 31, 2025 ($210,683 loss for the year ended March 31, 2024). The value ascribed to stock options granted during the year contributed to this small loss. Sales increased 4.9% to $9,673,002 this year compared to $9,219,948 for the year ended March 31, 2024.

SAN DIEGO, June 24, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (“Cidara”) (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today announced the pricing of an underwritten public offering of 7,954,546 shares of its common stock at a price to the public of $44.00 per share. All of the shares are to be sold by Cidara.

Plant-Based Ingredients, Scientific Research, and Mineral Synergy Come Together in This Modern Approach to Natural Weight Support

PHILADELPHIA, June 24, 2025 (GLOBE NEWSWIRE) -- Barrack, Rodos & Bacine is actively investigating a data breach at Aflac Incorporated.